Clinical Research Directory

Inclusion Criteria: * Aged 75 years and above * Standard treatment is ineffective (disease progresses after treatment) or locally advanced or metastatic malignant solid tumor patients who cannot tolerate standard therapy, cannot receive or do not have standard therapy * ECOG(Eastern Cooperative Oncology Group) performance is 0-3 * Life expectancy greater than 3 months * serum aspartate transaminase (AST) and serum alanine transaminase (ALT) ≤3.0\*ULN, or AST and ALT≤5\*ULN with hepatic metastasis; Total serum creatinine ≤1.5\*ULN * Signed informed consent form Exclusion Criteria: * Current pregnancy or lactation * History of other malignant tumors within 5 years prior to dose administration, expect for#malignancies that can be cured after treatment (including but not limited to adequately treated thyroid cancer, cervical carcinoma in situ, basal or squamous cell skin cancer) * Uncontrolled epilepsy, central nervous system diseases or mental illness * arrhythmia, congestive heart failure, or greater than or equal to Class 2 congestive heart failure as defined by the New York Heart Association Functional Classification, or history of myocardial infarction unstable angina, or acute coronary syndrome within 6 months prior to enrollment in the study * Received allogeneic hematopoietic stem cell transplantation or solid organ transplantation * Other serious, uncontrolled concomitant diseases that may affect protocol compliance or interpretation of outcomes, including active opportunistic infections or advanced (severe) infections, uncontrolled diabetes * Allergic to any of the ingredients used in the study * A history of immunodeficiency, including HIV positive or other acquired or congenital immunodeficiency disease, or a history of organ transplantation, or other immune-related disease requiring long-term oral hormone therapy * Acute and chronic tuberculosis infection * Other disorders with clinical significance according to the researcher's judgment